-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Global Initiatives
-
Climate Change-Fueled Natural Disasters and the Impacts on Lung Cancer Care
In our continuing series on role the environment plays in thoracic oncology, Dr. Roselle De Guzman outlines the risks posed by our changing climate and the potential benefits of taking a proactive approach to reduce those risks.
-
Healthcare Community Can Still Take Action to Combat Effects of Climate Change
Dr. Leticia Nogueira says the time has come for the lung cancer community to champion environmentally responsible practices that help mitigate cancer risks and outcomes.
-
In Brief for February 26, 2025
Durvalumab is recommended for approval in the EU, Health Canada approves pembrolizumab, and the US FDA grants priority review to datopotamab deruxtecan.
-
Climate Change Increasingly Exposes Communities, Healthcare Systems to Unpredictable Circumstances
The American Cancer Society’s Dr. Leticia Nogueira says lung cancer epitomizes the severe and inescapable threats climate change pose to cancer control activities.
-
In Brief for February 12, 2025
The US FDA grants fast track designation to treat KRAS G12C-mutant metastatic NSCLC and China’s NMPA approves taletrectinib for advanced ROS1-positive NSCLC.
-
Experts Share New Insights, Key Updates During Final Plenary Session of the 2024 ACLC
Takeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment.
-
Amivantamab-Vmjw Plus Lazertinib Shows Statistically Significant and Clinically Meaningful Improvement in Overall Survival Versus Osimertinib Alone
The combination treatment is the first and only regimen to show a survival benefit that surpasses the current standard of care for EGFR-mutated lung cancer.
-
Strength in Numbers: Researchers and Advocacy Groups Unite to Decode the Impact of Genetics on Lung Cancer Risk
A new genetics study aims to collect data from 10,000 participants diagnosed with lung cancer to improve future outcomes and enhance research.
-
In Brief for January 22, 2025
FDA issues draft guidance on the use of AI for biological and drug product submissions, China’s NMPA grants priority review for the combination of savolitinib and osimertinib, and nivolumab and hyaluronidase-nvhy receive FDA approval for subcutaneous injection.
-
Future Directions in Lung Cancer Treatment
During the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives.